It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Jaypirca and Omvoh should also contribute meaningfully through the end of the decade. In other words, Eli Lilly's revenue should continue growing at a good clip. The midpoint of the company's ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid growth in recent years has been largely fueled by the success ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

These include Alzheimer's disease treatment Kisunla, eczema therapy Ebglyss, and ulcerative colitis drug Omvoh. These medicines aren't yet contributing to Eli Lilly's already impressive top-line ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving ...

Eli Lilly and Company discovers ... and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized ...